HongZhang BeijingChina

Wcn26 Post edited Speaker Card

https://storage.unitedwebnetwork.com/files/486/777412-35623-Hong Zhang_363132.png

Time	Session

9:25 a.m. 10:55 a.m.	B Cell Targeting in Glomerular Disease SK A Role for Kidney Resident B/plasma Cells in Kidney Disease Progression? HeatherReich Speaker Heather.Reich@uhn.caCanada B Cell Activating Factor and A Proliferation-inducing Ligand Signaling in Glomerular Disease HongZhang Speaker hongzh@bjmu.edu.cnChina B Cell Targeted Therapies in Glomerular Diseases RichardLafayette Speaker czar@stanford.eduUnited States The Future of B Cell Therapies in the Treatment of Glomerular Diseases Jonathan Barratt Speaker jb81@leicester.ac.ukUnited Kingdom Q&A Session 503
5 p.m. 6 p.m.	Industry Symposium 26 YusukeSuzuki Moderator yusuke@juntendo.ac.jpJapan Evolving Landscape of IgA Nephropathy in 2026 and Beyond HongZhang Speaker hongzh@bjmu.edu.cnChina 303

Time	Session

12:50 p.m. 1:50 p.m.	Industry Symposium 47 BradRovin Moderator rovin.1@osu.eduUnited States Intro + IgAN Case: Global Perspective BradRovin Speaker rovin.1@osu.eduUnited States IgAN Case: China Perspective HongZhang Speaker hongzh@bjmu.edu.cnChina IgAN Case: Japan Perspective HITOSHISUZUKI Speaker shitoshi@juntendo.ac.jpJapan 301 - 302
2:10 p.m. 3:10 p.m.	Hot Debate: Complement Inhibition vs Nefecon in IgA Nephropathy – Which First for Patients at Risk? BKH Complement Inhibition Should Be Considered Before Nefecon in Patients With IgAN at Risk of Progression VladoPerkovic Speaker vlado.perkovic@unsw.edu.auAustralia Nefecon Should Be Considered Before Complement Inhibition in Patients With IgAN at Risk of Progression HongZhang Speaker hongzh@bjmu.edu.cnChina 501 - 502